Nicholas Chinedu Obitte

Nicholas Chinedu Obitte

Auto-generated profile, based on publicly available information

Nicholas Chinedu Obitte

Department of Pharmaceutical Technology and Industrial Pharmacy, Faculty of Pharmaceutical Sciences

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
CAChukwuma O. Agubata
Chukwuma O. Agubata
COChiadikaobi Okereke
Chiadikaobi Okereke
INIfeanyi T. Nzekwe
Ifeanyi T. Nzekwe
RORemigius I. Onoja
Remigius I. Onoja
NONicholas C. Obitte
Nicholas C. Obitte

1 November 2016 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
PNPetra Obioma Nnamani
Petra Obioma Nnamani
AUAgatha Adaora Ugwu
Agatha Adaora Ugwu
EIEmmanuel Chinedu Ibezim
Emmanuel Chinedu Ibezim
FKFranklin Kenechukwu
Franklin Kenechukwu
PAPaul Achile Akpa
Paul Achile Akpa
AAAnthony Amaechi Attama
Anthony Amaechi Attama
The present study aimed to develop low-dose liquisolid tablets of two antimalarial drugs artemether–lumefantrine (AL) from a nanostructured lipid carrier (NLC) of lumefantrine (LUM) and estimate the potential of AL as an oral delivery system in malariogenic Wistar mice. LUM-NLCs were prepared by hot homogenization using Precirol® ATO 5/Transcutol® HP and tallow fat/Transcutol® HP optimized systems containing 3:1 ratios of the lipids, respectively, as the matrices. LUM-NLC characteristics, including morphology, particle size, zeta potential, encapsulation efficiency, yield, pH-dependent stability, and interaction studies, were investigated. Optimized LUM-NLCs were mixed with artemether powder and other dry ingredients and the resultant powder evaluated for micromeritics. Subsequent AL liquisolid tablets were tested for in vitro drug release and in vivo antiplasmodial activity in mice infected with Plasmodium berghei berghei (NK 65). Results showed that optimized LUM-NLC were stable, spherical, polydispersed but nanometric. Percentage yield and encapsulation efficiency were ~92% and 93% for Precirol® ATO 5/Transcutol® HP batch, then 81% and 95% for tallow fat/Transcutol® HP batch while LUM was amorphous in NLC matrix. In vitro AL release from liquisolid compacts revealed initial burst release and subsequent sustained release. Liquisolid tablet compacts formulated with Precirol® ATO 5/Transcutol® HP-AL4 achieved higher LUM release in simulated intestinal fluid (84.32%) than tallow fat/Transcutol® HP-BL3 (77.9%). Non-Fickian (anomalous) diffusion and super case II transport were the predominant mechanisms of drug release. Equal parasitemia reduction was observed for both batches of tablet compacts (~92%), superior to the reduction obtained with commercial antimalarial formulations: Coartem® tablets (86%) and chloroquine phosphate tablets (66%). No significant difference (P<0.05) in parasite reduction between double (4/24 mg/kg) and single (2/12 mg/kg) strength doses of AL compacts was observed. Our result highlights that AL could be formulated in much lower doses (4/24 mg/kg), for once-in-two days oral administration to improve patient compliance, which is currently not obtainable with conventional AL dosage forms.

1 January 2013 in AIDS Research and Therapy
Verified
Journal Article
Open access
PDF file
NONicholas C Obitte
Nicholas C Obitte
Lisa Cencia RohanLisa Cencia Rohan
Lisa Cencia Rohan
CAChristianah M Adeyeye
Christianah M Adeyeye
MPMichael Parniak
Michael Parniak
CECharles O Esimone
Charles O Esimone
CSIC (5-chloro-3-phenylsulfonylindole-2-carboxamide), a non-nucleoside reverse transcriptase inhibitor (NNRTI) has not been advanced as a therapeutic anti-HIV candidate drug due to its low aqueous solubility and poor bioavailability.

20 March 2014 in Journal of Pharmaceutics
Verified
Journal Article
Open access
PDF file
NONicholas C. Obitte
Nicholas C. Obitte
KOKenneth C. Ofokansi
Kenneth C. Ofokansi
FKFranklin Kenechukwu
Franklin Kenechukwu
In this study, goat fat (Capra hircus) and melon oil were extracted and used to formulate self-nanoemulsifying drug delivery systems (SNEDDS) based on either goat fat alone or its admixture with melon oil by employing escalating ratios of oil(s), surfactant blend (1:1 Tween 60 and Tween 80), and cosurfactant (Span 85), with or without carbosil, a glidant, for the delivery of indomethacin. The formulations were encapsulated in hard gelatin capsules and then assessed using isotropicity test, aqueous dilution stability and precipitation propensity, absolute drug content, emulsification time, in vitro drug release, and anti-inflammatory activity. The SNEDDS exhibited low precipitation propensity and excellent stability on copious dilution, as well as high drug release in vitro and in vivo. The inhibition produced by the SNEDDS was comparable to that of indomethacin injection (positive control) for much of the 5h test period, indicating a high degree of bioavailability of the administered SNEDDS. The absolute drug contents and emulsification times fell within narrow limits. This study has shown that a 1:1 ratio of melon oil and goat fat could confer favourable properties with respect to drug release and anti-inflammatory activity on SNEDDS for the delivery of indomethacin, thus encouraging further development of the formulations.

1 January 2011 in Asian Journal of Pharmaceutics
Verified
Journal Article
Closed access
PDF file
NONicholasC Obitte
NicholasC Obitte
ACAmarauche Chukwu
Amarauche Chukwu
The overall objective of this present investigation was to determine the synergistic potentiality of Landolphia owariensis latex (LOL) and Eudragit® L-100 as hydrophobic polymeric agents in ensuring controlled drug release for possible colon-targeted delivery of metronidazole. Metronidazole granules were prepared by the wet granulation method and manually encapsulated. The entire capsule surface was first coated with Eudragit® L-100 (primary coating). Secondly half (50%) or five-sixth (5/6 or 83%) of the capsule surface was coated atop the primary coating with LOL (secondary coating). Two different granule size fractions were isolated and compared. Parallel gradient in vitro drug release studies were carried out in media of pH 1.2, 6.8 and 7.4, respectively. The dissolution data were subjected to kinetic treatment. Results showed that the least quantity of drug release took place at pH 1.2 followed by pH 6.8, with greatest drug release taking place at pH 7.4. Capsule surface coated with LOL significantly (P<0.05) affected drug release and time of release. Matrix former (binder) concentration had no significant (P<0.05) effect on drug release, but particle size did. More than one drug release mechanisms were operational and most capsules with 50% surface coated with LOL recorded higher Dissolution efficiency (DE) but lower Mean dissolution time (MDT) than those of 83%. In conclusion, the use of Eudragit® L-100 and LOL as primary and secondary capsule coatings respectively have demonstrated competence in controlling drug release and thus may hold promise at preferentially targeting metronidazole to the colon against amebic diseases.

15 December 2013 in African Journal of Pharmacy and Pharmacology
Verified
Journal Article
Open access
PDF file
COC. Obitte
C. Obitte
NON. C. Obitte
N. C. Obitte
KOK. C. Ofokansi
K. C. Ofokansi
SCS. A. Chime
S. A. Chime
DOD. C. Odimegwu
D. C. Odimegwu
UOU. E Odoh
U. E Odoh
The non-steroidal anti-inflammatory drug (NSAID), indomethacin, is disadvantaged by its poor water solubility and gastrointestinal adverse effects. The aim of this work therefore was to formulate this drug into solid self emulsifying drug delivery system (SSEDDS) as an attempt to improve its aqueous solubility and anti-inflammatory property using shea butter or its blend with Bos indicus lipid. Proximate analysis was carried out on shea butter. Indomethacin-loaded SSEDDS containing lipid (shea butter, Vitellaria paradoxa), surfactant (Tween 65) and cosurfactant (Span 85) or lipid blends (shea butter/Bos indicus fat), surfactant blends (Tween 65/Tween 80) and cosurfactant (Span 85) were formulated. The drug-loaded SSEDDS were evaluated for visual isotropicity, emulsification time, aqueous dilution, refrigeration test, loading efficiency, in vitro drug release and anti-inflammatory properties. Results showed that Shea butter contained 92.8% fat, 1.52% moisture, 2.05% protein, 9.78% carbohydrate and trace amounts of fiber and ash. Pre/post formulation isotropicity tests showed that all batches of indomethacin SSEDDS were stable. SSEDDS containing shea butter as the lipid component recorded significantly (p < 0.05) longer emulsification times than those containing lipid blends. The T85 of most of the batches was within 30 min. Shea butter-based SSEDDS demonstrated significantly (p < 0.05) higher anti-inflammatory effect than unformulated indomethacin powder. In conclusion, Shea butter conferred stability to the formulations and contributed to acceptable in vitro and superior anti-inflammatory characteristics of indomethacin. Key words: Shea butter, Bos indicus fat, indomethacin, solid self emulsifying drug delivery system (SEDDS), anti-inflammatory.